Scientific deep-dive
Does Zepbound Cause Headaches? Frequency, Mechanism & Relief Evidence Review
Headache on Zepbound (tirzepatide) is common but was not more frequent than placebo in SURMOUNT-1's registry results (7.0-8.0% vs 7.3%), and it is not in the label's adverse-reaction table. Triggers, relief protocol, red flags, and the Wegovy comparison.
The honest short answer:
Headache was not clearly more common on Zepbound (tirzepatide) than on placebo in the main trials. It is not among the adverse reactions in Section 6.1 of the Zepbound prescribing information, which lists reactions seen in at least 2% of patients and more often than with placebo[6]. In the SURMOUNT-1 results posted on ClinicalTrials.gov, headache was reported by 7.5% at 5 mg, 8.0% at 10 mg, and 7.0% at 15 mg versus 7.3% on placebo[7]. Headaches still happen on Zepbound, as they do on placebo, and dehydration from nausea, vomiting, or low fluid intake is a common trigger. Most respond to active hydration, electrolytes, acetaminophen, and dose stability. A small share need prescriber attention — the red flags are at the end of this article.
“Zepbound headache” is one of the most-searched practical questions on tirzepatide. The honest answer involves three things: how often it actually happened in the Phase 3 trials, what is plausibly driving it when it does happen, and how to tell ordinary titration headache from something that needs urgent care. This article walks through the SURMOUNT-1 adverse-event results, the Zepbound label’s Section 6.1 table, the data from SURMOUNT-4 (maintenance trial), SURMOUNT-OSA (sleep apnea population), and SUMMIT (HFpEF population), the comparison to semaglutide’s STEP-1 headache rate, the mechanism options that the published literature supports, and the practical relief protocol used in clinical practice.
What SURMOUNT-1 actually measured
SURMOUNT-1[1] was the Phase 3 pivotal trial that supported the FDA approval of Zepbound for chronic weight management. It randomized 2,539 adults with BMI ≥30 (or ≥27 with at least one weight-related comorbidity, excluding diabetes) to weekly tirzepatide 5 mg, 10 mg, 15 mg, or placebo for 72 weeks. Its adverse-event results are posted on ClinicalTrials.gov[7]. The table below uses those counts, which cover every randomized participant who received at least one dose, with safety follow-up up to week 193 in the registry record.
| Adverse event | Tirz 5 mg | Tirz 10 mg | Tirz 15 mg | Placebo |
|---|---|---|---|---|
| Headache | 7.5% | 8.0% | 7.0% | 7.3% |
| Nausea | 25.4% | 34.1% | 31.9% | 9.8% |
| Diarrhea | 20.3% | 22.5% | 23.7% | 7.9% |
| Vomiting | 9.2% | 11.6% | 12.9% | 1.9% |
Read the headache row carefully. Every tirzepatide dose sits within 1 percentage point of placebo, and the top dose (7.0%) came in slightly below placebo (7.3%). There is no dose–response: nausea rises from 9.8% on placebo to 25.4–34.1% on tirzepatide and vomiting from 1.9% to 9.2–12.9%, while headache stays flat. Headache is not a drug-specific safety signal in SURMOUNT-1. The GI cluster is.
Two practical implications follow. First, about 7 of every 100 placebo participants reported a headache, the same share as on tirzepatide, so many headaches that patients attribute to Zepbound would plausibly have occurred anyway. Second, headache is not a reason to stay at a sub-effective dose. The weight-loss difference between 5 mg (−15.0% body weight) and 15 mg (−20.9%) is large[1]; the headache difference in the registry counts is less than 1 percentage point.
Does the signal hold up in the other Zepbound trials?
SURMOUNT-1 is one trial. The strongest evidence for a real drug-related adverse-event signal is replication across independent trials in different populations. Tirzepatide has now been studied in four major Phase 3 programs relevant to Zepbound: SURMOUNT-1 (general obesity)[1], SURMOUNT-4 (maintenance of weight reduction after a 36-week lead-in)[2], SURMOUNT-OSA (obstructive sleep apnea with obesity)[3], and SUMMIT (heart failure with preserved ejection fraction with obesity)[4]. Gastrointestinal events dominate the adverse-event profiles, but headache shows no consistent excess in the posted registry results. SURMOUNT-4 reported headache in 7.2% during the open-label tirzepatide lead-in, then 1.5% on continued tirzepatide versus 3.0% after the switch to placebo[9]. The two SURMOUNT-OSA trials reported 3.5% versus 2.5% on placebo and 0% versus 0.9%[10]. In SUMMIT, headache was not among the adverse events reported in at least 5% of either group[11].
That consistency matters because the populations differ. SURMOUNT-1 enrolled adults with obesity broadly, SURMOUNT-OSA enrolled adults with moderate-to-severe sleep apnea, and SUMMIT enrolled adults with HFpEF. The trial durations differ too: 72 weeks for SURMOUNT-1, 88 weeks for SURMOUNT-4 (36-week lead-in plus 52-week maintenance), 52 weeks for SURMOUNT-OSA, and the SUMMIT primary endpoint at 52 weeks. Across those populations and exposure windows, headache on tirzepatide stayed close to the placebo rate.
Mechanism: what can trigger headache on Zepbound
The trials do not show tirzepatide causing headache directly, but several things that happen on the drug are classic headache triggers. Four candidates map onto the pattern patients describe.
1. Dehydration from blunted thirst drive
Tirzepatide acts on central GLP-1 and GIP receptor populations that overlap with hypothalamic circuits regulating both hunger and thirst. In the first weeks of therapy — particularly after each titration step — patients commonly describe reduced spontaneous thirst alongside reduced spontaneous hunger. The result is mild chronic underhydration, which is a classical headache trigger. Active hydration (tracked, not thirst-driven) is the first-line clinical response and is the intervention most likely to resolve titration-phase headaches without dose changes. The Zepbound DailyMed label[6] specifically calls out dehydration as a precipitating factor for acute kidney injury — the same dehydration mechanism is the leading candidate for headache.
2. GI side effects compounding the hydration deficit
Nausea (25–29% across doses vs 8% on placebo in the Zepbound label’s pooled weight-reduction trials)[6], vomiting (8–13% vs 2%), and diarrhea (19–23% vs 8%) directly reduce fluid intake and increase fluid loss. Patients in titration with active GI symptoms run a double hydration deficit: decreased intake from reduced appetite plus increased output from GI symptoms. When a headache follows, dehydration and electrolyte loss are the likely route. That fluid-loss route is the main mechanism in the class-wide GLP-1 headache evidence as well.
3. Glucose fluctuations
Tirzepatide is a glucose-dependent insulin secretagogue and improves glycemic control. The clinically important risk is in patients also taking insulin or a sulfonylurea. In the Zepbound label’s trial of patients with type 2 diabetes, hypoglycemia below 54 mg/dL occurred in 4.2% on Zepbound versus 1.3% on placebo, and in 10.3% of Zepbound patients taking a sulfonylurea versus 2.1% of those not taking one; the label says the insulin or insulin secretagogue dose may need to be reduced[6]. Hypoglycemic headache is real and is one of the few situations in which a Zepbound headache is an early warning sign of a more serious underlying event.
4. Rapid weight loss, blood pressure shifts, and posture
Rapid weight loss on its own — from any cause — is associated with blood-pressure changes that can produce headache, particularly in patients on antihypertensives whose doses become relatively over-aggressive as systolic pressure drops. The SUMMIT trial[4] in HFpEF patients and the SURMOUNT-OSA trial[3] in sleep apnea patients both enrolled populations on baseline antihypertensives. Postural light-headedness and tension-type headache often emerge in the first 4–8 weeks of therapy and respond to prescriber-supervised antihypertensive dose adjustment rather than to OTC analgesics.
Practical relief protocol
The clinical management pattern for Zepbound titration-phase headache is conservative and stepwise. None of these steps requires changing the Zepbound regimen for most patients.
- Active hydration, not thirst-driven. Target 64–80 oz (2–2.5 L) of fluid per day, tracked rather than estimated. Set timed reminders if necessary. Plain water counts. Sugary drinks should be limited because they trade hydration for caloric load. The Zepbound DailyMed label[6] specifically warns about dehydration driving acute kidney injury — the hydration target is a safety priority beyond just headache.
- Electrolytes during active GI symptoms. Oral rehydration salts (the WHO formulation or commercial equivalents like Liquid IV, LMNT, or Pedialyte) are preferable to plain water when a patient is actively losing fluid through vomiting or diarrhea. Plain-water rehydration in the setting of GI losses can produce dilutional hyponatremia, which is itself a headache trigger.
- Acetaminophen, not ibuprofen, as first-line OTC. Acetaminophen (Tylenol, paracetamol) is not specifically flagged on the Zepbound label as a concern. Ibuprofen and other NSAIDs compound the renal-perfusion risk that dehydration already creates — the Zepbound label warns of postmarketing acute kidney injury cases following dehydration from GI side effects[6], and NSAIDs worsen that profile. Patients with liver conditions or on other hepatotoxic medications should confirm acetaminophen dosing with a prescriber or pharmacist.
- Stay at the current dose if headache emerges mid-titration. The standard prescriber response to a difficult titration step is to stay at the current dose for an additional 4 weeks rather than escalate on schedule. The Zepbound label permits flexible titration. Patients who push through escalation with active headache often regret it; an extra month at 5 mg or 7.5 mg is almost always the right move.
- Caffeine intake matters. Patients who reduce overall beverage intake on Zepbound sometimes inadvertently reduce caffeine intake too — caffeine withdrawal headache is real and resolves with a steady, modestly reduced caffeine pattern rather than abrupt discontinuation. Dependence develops at fairly low regular intakes (as little as 100 mg a day), and withdrawal headache typically starts 12–24 hours after intake drops, peaking at 20–48 hours. If headaches arrive in the first day or two after starting or stepping up and you are a regular coffee drinker, keep your usual caffeine from a non-caloric source (black coffee, tea) while cutting other caloric drinks.
- Hydrate ahead on injection day. Some patients find headaches cluster in the 24–72 hours after the weekly injection, when appetite and thirst suppression are strongest. A practical habit is a full glass of water every 2 hours on injection day and the day after, rather than waiting to feel thirsty.
- Discuss antihypertensive dose adjustment with the prescriber if blood pressure runs low. Rapid weight loss frequently makes antihypertensive doses too aggressive. Home blood pressure monitoring (a $25 cuff is enough) gives the prescriber the data to adjust safely. Do not self-adjust blood pressure medications.
If you take bupropion (Wellbutrin or Contrave)
Bupropion carries a dose-dependent seizure risk that rises with medications that lower the seizure threshold, and some patients on Wellbutrin (bupropion SR or XL) or Contrave (naltrexone + bupropion ER) also use or are prescribed headache medications. Confirm with your prescriber or pharmacist before adding any new medication, OTC or prescription, if you are on a bupropion-containing drug.
Compounded tirzepatide and headaches
Compounded tirzepatide from 503A pharmacies contains the same active molecule as Zepbound and Mounjaro. The headache mechanism is pharmacological (appetite and thirst suppression leading to dehydration), not a product of the brand, so patients on compounded tirzepatide should expect the same headache profile, the same management steps, and the same warning signs described here. The FDA-approved labeling is cited because it reflects the controlled-trial data[1]; compounded tirzepatide has not been separately studied in clinical trials and carries added uncertainty from variability in compounding quality and excipients.
Red flags — when a Zepbound headache is not just titration
Most Zepbound headaches are mild, dehydration-driven, and resolve with the steps above. A small share are warning signs of something serious. The clinical pattern below should prompt immediate evaluation regardless of medication status.
Seek urgent or emergency care for any of:
- Sudden, severe headache (“thunderclap,” the worst headache of your life) — emergency evaluation to rule out subarachnoid hemorrhage.
- Headache plus new vision changes — particularly blurred or double vision, transient vision loss, or visual field cuts. Vision changes plus headache is the cardinal presentation of idiopathic intracranial hypertension (IIH), discussed below.
- Headache plus neurologic symptoms — facial drooping, arm or leg weakness, speech difficulty, confusion, severe dizziness. These can be stroke or transient ischemic attack and require immediate evaluation.
- Fever with stiff neck — rule out meningitis.
- Headache with hypoglycemia symptoms (shakiness, sweating, palpitations, confusion) in patients on concomitant insulin or sulfonylurea. Check glucose and treat per the prescriber’s hypoglycemia plan.
- Headache that persists for >4 weeks at a stable dose, particularly if it is worsening rather than improving.
The IIH question
Idiopathic intracranial hypertension (IIH) — previously called pseudotumor cerebri — is a syndrome of elevated intracranial pressure without a structural cause, classically presenting with headache and vision changes. Case reports in the published literature have described IIH in patients on GLP-1 receptor agonists, but the data is at the case-report level. IIH is also strongly associated with obesity itself and with rapid weight changes in either direction — making the causal attribution to the drug versus to the weight trajectory difficult. The Zepbound DailyMed label[6] does not list IIH in Section 6 (adverse reactions) as of the current revision. Oddly, the class also shows up on the treatment side: exenatide lowered intracranial pressure in an IIH trial.
The pragmatic implication is not that Zepbound causes IIH at any meaningful rate — that has not been established. The implication is that a Zepbound patient who develops headache plus visual symptoms should be evaluated for IIH the same as any other patient with that presentation, because IIH is treatable and progressive visual loss is the worst-case outcome of an untreated case. Visual symptoms in the setting of headache are the trigger to call the prescriber the same day, not the next visit.
How Zepbound headache compares to Wegovy (semaglutide)
STEP-1[5] is the parallel pivotal trial for semaglutide 2.4 mg, the active ingredient in Wegovy. In STEP-1’s results on ClinicalTrials.gov, headache was reported by 15.2% of semaglutide-treated patients versus 12.2% on placebo[8], a gap of about 3 percentage points. SURMOUNT-1 showed no gap (7.0–8.0% on tirzepatide vs 7.3% on placebo)[7], but the cross-trial comparison requires extreme caution. STEP-1 and SURMOUNT-1 enrolled overlapping but non-identical populations, used different titration schedules, ran for different durations (68 weeks vs 72 weeks), and ascertained adverse events differently. No head-to-head randomized trial has compared headache incidence between tirzepatide and semaglutide as a primary or secondary endpoint in obesity populations. Patients evaluating the two drugs should not use the headache numbers as a tiebreaker — the GI tolerability, dose escalation schedule, and weight-loss magnitude differences carry far more decision weight. The full Wegovy picture, including why migraine is absent from its label, sits in Wegovy headaches and migraines.
Magnitude comparison
Headache rates in each trial's ClinicalTrials.gov results: tirzepatide in SURMOUNT-1 (Zepbound active ingredient) vs semaglutide 2.4 mg in STEP-1 (Wegovy active ingredient), against placebo rates from each trial. Cross-trial comparisons are suggestive, not conclusive: no head-to-head trial.[7][8]
- Semaglutide 2.4 mg (STEP-1, 68 wk)15.2 %Wegovy active ingredient
- Tirzepatide 15 mg (SURMOUNT-1, 72 wk)7.0 %Zepbound maximum dose
- Tirzepatide 10 mg (SURMOUNT-1, 72 wk)8.0 %
- Tirzepatide 5 mg (SURMOUNT-1, 72 wk)7.5 %starting maintenance dose
- Placebo (STEP-1, 68 wk)12.2 %
- Placebo (SURMOUNT-1, 72 wk)7.3 %about the same as the tirzepatide arms
The chart makes one point clear: the placebo background rate of headache is substantial in both trials, and the excess over placebo is small with semaglutide (about 3 points) and absent with tirzepatide. Headache is not a differentiating safety signal between Zepbound and Wegovy. For the broader side-effect comparison between the two, see our Zepbound vs Wegovy side-effects comparison and the GLP-1 side-effects evidence review covering the full STEP-1 vs SURMOUNT-1 cross-trial picture.
Bottom line for the “Zepbound headache” question
- Headache is common, but not more common than on placebo. 7.0–8.0% across the three SURMOUNT-1 doses vs 7.3% on placebo in the registry results, and headache is not in the Zepbound label’s adverse-reaction table. The GI cluster is the real signal.
- When it happens, the triggers are plausibly multifactorial. Dehydration from blunted thirst drive, GI-induced fluid losses, glucose fluctuations (mostly in combination therapy), and blood pressure shifts from rapid weight loss. No single drug-receptor pathway has been established.
- First-line management is hydration plus acetaminophen. 64–80 oz/day tracked fluid intake, oral rehydration salts during active GI symptoms, acetaminophen rather than ibuprofen, and dose stability through difficult titration weeks. Most titration headaches resolve in 2–4 weeks at a stable dose.
- Red flags are urgent. Sudden severe headache, headache with vision changes, headache with neurologic symptoms, fever plus stiff neck, hypoglycemia symptoms in combination-therapy patients, and headache persisting >4 weeks at a stable dose all warrant prescriber contact or emergency evaluation.
- The IIH question is real but case-report-level. Vision changes plus headache should always prompt evaluation — not because Zepbound is a confirmed cause of IIH, but because IIH is treatable and progressive vision loss is preventable.
- Headache should not be the tiebreaker between Zepbound and Wegovy. Registry data show a small excess over placebo with semaglutide in STEP-1 (15.2% vs 12.2%) and none with tirzepatide in SURMOUNT-1, but the comparison is not head-to-head and the difference is small. Pick on weight-loss magnitude, GI tolerability, dose schedule, and cost — not on headache.
For the operational question of how to titrate through the first weeks of Zepbound without losing tolerability, see our GLP-1 side-effect Q&A hub. For the broader Zepbound clinical picture, the Zepbound drug page consolidates pricing, dose tiers, FDA-approved indications, and provider availability.
Our reviews
Providers that offer tirzepatide
Telehealth providers we’ve reviewed. Each opens our full, independent review.
Featured partners
Partners · our scores never change
- Editorial score: 7.2. Read our review of HumeCare+GLP-1 weight loss with real-time body-composition tracking to protect muscleFrom$299/mocompounded
- Editorial score: 7.2. Read our review of LttlEvery commitment tier priced openly, plus a low-dose microdose optionFrom$149/4 wksbilled per 4 weekscompounded
- Editorial score: 7.1. Read our review of AgelessRxLongevity-focused GLP-1 care with microdosing and brand-name optionsFrom$209/momicrodose, 2-month plan ratecompounded
- Editorial score: 7.1. Read our review of Bodybuilding Health+Fitness-brand compounded GLP-1 with hormone and performance programsFrom$209/mostarting dosecompounded
- Editorial score: 7.0. Read our review of Midi HealthMenopause-focused care with GLP-1 as a metabolic adjunctFrom$210/4 wksbilled per 4 weekscompounded
We may earn a commission from featured partners. Learn more
See the full ranking →Frequently Asked Questions
References
- 1.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. PMID: 35658024.
- 2.Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, Ahmad NN, Zhang S, Liao R, Bunck MC, Jouravskaya I, Murphy MA; SURMOUNT-4 Investigators. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. PMID: 38078870.
- 3.Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, Sands SA, Schwab RJ, Dunn JP, Chakladar S, Bunck MC, Bednarik J; SURMOUNT-OSA Investigators. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024. PMID: 38912654.
- 4.Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, Ge J, Weerakkody GJ, Ou Y, Bunck MC, Hurt KC, Murakami M, Borlaug BA; SUMMIT Trial Study Group. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025. PMID: 39555826.
- 5.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. PMID: 33567185.
- 6.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information. DailyMed (NIH). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- 7.Eli Lilly and Company. A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1, NCT04184622): results and adverse events. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT04184622
- 8.Novo Nordisk A/S. STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (NCT03548935): results and adverse events. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT03548935
- 9.Eli Lilly and Company. SURMOUNT-4 (NCT04660643): results and adverse events. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT04660643
- 10.Eli Lilly and Company. SURMOUNT-OSA (NCT05412004): results and adverse events. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT05412004
- 11.Eli Lilly and Company. SUMMIT: A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity (NCT04847557): results and adverse events. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT04847557
Related research
Does Zepbound Cause Fatigue? Label Rates, Mechanism & Management Evidence
Zepbound (tirzepatide) fatigue is a listed FDA adverse reaction: the label's pooled trials report 5% at 5 mg, 6% at 10 mg, 7% at 15 mg vs 3% on placebo. Caloric deficit is the load-bearing mechanism. Timeline, labs to check, sleep + protein protocol, and Wegovy comparison.
13 min read
Does Wegovy Cause Migraines or Headaches? FDA Label & Trial Evidence Review
Wegovy (semaglutide 2.4 mg) FDA label §6.1 reports headache at 14% vs 10% placebo. Migraine is NOT listed on the label. The only migraine signal is a 2025 FAERS class-level reporting ratio of 1.28 — hypothesis-generating, not causal. Dehydration is the load-bearing mechanism.
13 min read
Zepbound Nausea: SURMOUNT-1 Rates, Mechanism, Timeline & Evidence-Based Relief Protocol
Nausea is the most common Zepbound side effect. The Zepbound label reports 28% on tirzepatide 15 mg vs 8% placebo over 72 weeks, lower than the 44% on the Wegovy label. Guide covers dual GIP+GLP-1 mechanism, titration timeline, relief protocol, pancreatitis red flags.
13 min read
Why Does Tirzepatide / Semaglutide Make You Tired? GLP-1 Fatigue: Onset, Mechanism, and Management
Fatigue is a listed adverse reaction on GLP-1 labels: 11% on Wegovy versus 5% on placebo, and up to 7% on Zepbound at 15 mg versus 3%. Causes include eating too little, dehydration, and low blood sugar. It usually fades within 2 to 4 weeks at a stable dose.
14 min read
Does Mounjaro Cause Dizziness? FDA Label, Mechanisms & Management Evidence Review
Dizziness is not a separate line in Mounjaro's adverse-reaction table; the label lists it as a symptom of hypoglycemia (with insulin or a sulfonylurea) and of serious allergic reactions. Other causes: dehydration from GI losses and low blood pressure on standing.
13 min read
Mounjaro Nausea: How Long It Lasts, Why It Happens & How to Manage It
Mounjaro (tirzepatide for T2D) nausea is the most common adverse reaction, reported in 12-18% of patients on the three approved doses vs 6% on placebo in SURPASS-1. Dual GIP+GLP-1 gastric-emptying delay plus central nausea-circuit activation; diabetic gastroparesis compounds.
14 min read
Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Collective
The lowest flat medication price if you can absorb an annual membership fee
Read full review →From $69/mo
+ required membership
CoreAge Rx
Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
Read full review →From $129/mo
starting price
From $129/mo
sale price